Cochrane Review Group
Neonatal
210 systematic reviews in Neonatal ask 2,353 questions. 18.4% have no studies to answer them, 25.9% rest on very low certainty evidence and 20.3% reach moderate or high certainty.
Reviews
210
Questions
2,353
current versions
No studies
18.4%
Moderate or high
20.3%
No studies 432 · 18.4%Ungraded 99 · 4.2%Very low 609 · 25.9%Low 737 · 31.3%Moderate 385 · 16.4%High 91 · 3.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Salbutamol vs placebo Adverse effects of bronchodilators, including hypokalaemia, tachycardia, cardiac arrhythmia, tremor, hypertension and hyperglycaemia ‐ not reported · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Salbutamol vs placebo Pneumothorax · preterm infants (< 37 weeks GA) at risk of chronic lung disease Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants (2024) · Cochrane | no estimate extracted | 1 study · 173 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Pulmonary air leak, any (during first hospitalisation) Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Bronchopulmonary dysplasia (clinical definition) among survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 2.56 [0.11, 59.75] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | RR 0.17 [0.01, 3.37] | 1 study · 48 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with extubation at standard criteria (S‐ETT) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Death (all causes) during the first hospitalisation Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs no surfactant administration Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Intraventricular haemorrhage grade III and IV Anytime to discharge · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | 1 study · 50 participants | Very low |
Surfactant administration via laryngeal mask airway (S‐LMA) vs surfactant administration via endotracheal tube (ETT) with the intent to rapidly extubate (InSurE) Neurosensory disability in survivors · preterm infants with or at risk of respiratory distress syndrome Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants… (2024) · Cochrane | no estimate extracted | NR | No studies |
Reviews 210
Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit
CochraneSoF table
6 questions
Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants
CochraneSoF table
11 questions
Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates
CochraneSoF table
11 questions
Cromolyn sodium for the prevention of chronic lung disease in preterm infants
CochraneSoF table
7 questions
Feed thickener for infants up to six months of age with gastro‐oesophageal reflux
CochraneSoF table
6 questions
Calcium and phosphorus supplementation of human milk for preterm infants
CochraneSoF table
7 questions
Volume‐targeted versus pressure‐limited ventilation in neonates
CochraneSoF table
23 questions
Arginine supplementation for prevention of necrotising enterocolitis in preterm infants
CochraneSoF table
6 questions
Body positioning for spontaneously breathing preterm infants with apnoea
CochraneSoF table
33 questions
Fluid restriction for treatment of preterm infants with chronic lung disease
CochraneSoF table
4 questions
Sildenafil for pulmonary hypertension in neonates
CochraneSoF table
6 questions
Antibiotics for neonates born through meconium‐stained amniotic fluid
CochraneSoF table
13 questions
Neonatal vitamin A supplementation for the prevention of mortality and morbidity in term neonates in low and middle income countries
CochraneSoF table
8 questions
Saline irrigation for the management of skin extravasation injury in neonates
CochraneSoF table
1 questions
Skin‐to‐skin care for procedural pain in neonates
CochraneSoF table
7 questions
Topical anaesthesia for needle‐related pain in newborn infants
CochraneSoF table
7 questions
Routine oro/nasopharyngeal suction versus no suction at birth
CochraneSoF table
5 questions
Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn
CochraneSoF table
5 questions
Frenotomy for tongue‐tie in newborn infants
CochraneSoF table
4 questions
Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants
CochraneSoF table
6 questions
Cerebral near‐infrared spectroscopy monitoring for prevention of brain injury in very preterm infants
CochraneSoF table
8 questions
Orotracheal intubation in infants performed with a stylet versus without a stylet
CochraneSoF table
10 questions
Fluid supplementation for neonatal unconjugated hyperbilirubinaemia
CochraneSoF table
7 questions
Early planned removal of umbilical venous catheters to prevent infection in newborn infants
CochraneSoF table
3 questions
Clonidine for sedation and analgesia for neonates receiving mechanical ventilation
CochraneSoF table
2 questions